Lapachol

Otros Nombres

1,4-Naphthalenedione, 2-hydroxy-3-(3-methyl-2-butenyl)-1,4-Naphthoquinone, 2-hydroxy-3-(3-methyl-2-butenyl)-2-Hydroxy-3-(3-methyl-2-butenyl)-1,4-naphthalenedione2-Hydroxy-3-(3-methyl-2-butenyl)-1,4-naphthoquinone2-hydroxy-3-(3-methylbut-2-en-1-yl)-1,4-dihydronaphthalene-1,4-dione2-Hydroxy-3-(3-methylbut-2-en-1-yl)-1,4-naphthoquinone2-hydroxy-3-(3-methylbut-2-en-1-yl)naphthalene-1,4-dioneBethabarra WoodC.I. 75490C.I. Natural Yellow 16CI 75490GreenhartenGreenhartinGroenhartinIpe-Tobacco WoodLapachic acidLapachoLapachoic acidLapachol WoodNatural Yellow 16NSC 11905NSC 629756Pau d'arcoSurinam Greenheart WoodTaheeboTaigu WoodTaiguic acidTaiquic acidTecominZlut prirodni 16

Sinopsis

Lapachol: A Comprehensive Reference

1. Identity: Chemical and Botanical Classification

Chemical Identity

Lapachol is a hydroxy-1,4-naphthoquinone substituted by hydroxy and 3-methylbut-2-en-1-yl groups at positions 2 and 3, respectively. Its full systematic chemical name is 2-hydroxy-3-(3-methylbut-2-en-1-yl)-1,4-naphthoquinone, with the molecular formula C₁₅H₁₄O₃. It has a melting point of 139–140 °C and is classified as a prenylated naphthoquinone — a subtype of quinone built on the naphthalenic ring system.

Botanical Source and Distribution

Lapachol is a naturally occurring 1,4-naphthoquinone originally isolated by the Italian phytochemist E. Paterno from Tabebuia avellanedae (Bignoniaceae) in 1882 and subsequently found in several other genera belonging to the families of Leguminosae, Malvaceae, Plumbaginaceae, Lamiaceae, Arecaceae, Scrophulariaceae, Verbenaceae, Celastraceae, Avicenniaceae, Caesalpiniaceae, Rubiaceae, and Proteaceae.

Lapachol is a natural phenolic compound isolated from the bark of the lapacho tree, known botanically as Handroanthus impetiginosus, but formerly known by various other botanical names such as Tabebuia avellanedae. It is also found in other species of Handroanthus. Additional species confirmed to contain lapachol include Tabebuia flavescens, Tabebuia guayacan, Kigelia pinnata, Phyllarthron comorense, and Radermachera sinica. Lapachol is also a principal yellow coloring matter that occurs in the heartwood of teak (Tectona grandis L.f.) and Catalpa ovata.

The tree belongs mainly to the genus Handroanthus (including Handroanthus impetiginosus and Handroanthus chrysotrichus, among other species), although historically it was placed in the genus Tabebuia. It is naturally distributed in areas of Brazil, Argentina, Paraguay, Bolivia, Ecuador, Peru, Colombia, Mexico, and northern Uruguay.

Common Names and Synonyms

Lapacho, also called pau d'arco or taheebo, is a traditional herbal tea made from the inner bark of trees in the Handroanthus genus, native to South and Central America. In Portuguese, the tree is widely referred to as pau d'arco, which translates to "bow wood," reflecting the durable hardwood traditionally used by indigenous peoples to craft bows for hunting. Another name, taheebo, derives from the Tupi-Guarani term "tacyba bebuya," meaning "ant wood," alluding to the tree's hollow branches that often harbor ant colonies. In Brazil, it is also known as ipê roxo.

Plant Part Used and Preparations

Principally, the bark from the tree is the part employed, although the flowers and leaves are also used, depending on the ailment. The part of greatest health interest is the inner bark (the phloem), from which a purified decoction known as Taheebo is traditionally made. The bark of the tree, boiled in water (decoction), is taken as a tea or applied externally as a wash; the leaves and flowers are taken as a tea. Commercial products containing pau d'arco are available in capsule, tablet, extract, powder, and tea forms. Good quality pau d'arco (Tabebuia impetiginosa) contains an average of 4% to 6% lapachol (or 40 mg of lapachol per gram of pau d'arco bark/wood).

Analyses of commercial products show wide variation in species used, plant parts, and levels of lapachol and related compounds. Some "pau d'arco" capsules contain little or no characteristic naphthoquinones, which creates significant challenges for both research comparison and clinical application.

2. Traditional and Historical Use

Pre-Columbian and Indigenous Use

Lapacho, derived from the inner bark of trees in the genus Handroanthus (formerly Tabebuia), has been utilized in traditional medicine by indigenous South American cultures for over a millennium, with records suggesting its use predates the Inca civilization. The Incas employed it as a remedy for various ailments, while the Kallawaya healers of Bolivia, an itinerant group of Andean traditional practitioners, incorporated it into treatments for inflammatory conditions such as skin disorders.

Traditionally, the botanical drug is widely used in local and traditional phytomedicine, usually ingested as a decoction prepared from the inner bark of the tree to treat numerous conditions like bacterial and fungal infections, fever, syphilis, malaria, trypanosomiasis, as well as stomach and bladder disorders. As early as 1873, biomedical uses of Red Lapacho ("Pau d'Arco") were reported.

The indigenous peoples of various countries in Spanish and Portuguese America use the bark, leaves, and flowers to treat various conditions, including as an abortifacient, anti-anemic, antioxidant, antitumor, anti-inflammatory, anti-diabetic, antifungal, to promote wound healing, and against diverse parasites (including Leishmania, Schistosoma, Trypanosoma, and Toxocara).

Used since the time of the Inca civilization to treat infections, arthritis, and gastric ulcers, lapacho is widespread across a vast range from Mexico to Argentina. In northeastern Brazil, its inner bark is used as an analgesic, anti-inflammatory, antineoplastic, and diuretic by local peoples.

Entry into Biomedical Literature and the 20th-Century Revival

In 1967, after reports in the Brazilian press, pau d'arco came back to the light of clinicians and the public. The news magazine O'Cruzeiro started reporting "miraculous" cures in cancer patients in a hospital. Growing scientific interest in lapacho, intensifying since the late 1960s in Brazil, led to the identification of an extremely varied phytocomplex. This media attention catalyzed formal scientific investigation, including National Cancer Institute trials in the United States.

3. Key Constituents and Phytochemistry

Primary Active Compounds

The main bioactive compounds of lapacho include naphthoquinones, such as lapachol, and anthraquinones, known for their antimicrobial and antitumor activities. Quercetin, an antioxidant flavonoid, is also present in its bark. The inner bark is rich in active ingredients such as lapachol, beta-lapachone, quercetin, and anthocyanins.

Lapachol (2-hydroxy-3-(3-methylbut-2-en-1-yl)naphthalene-1,4-dione, C₁₅H₁₄O₃), which has anticancer properties, was the first naphthoquinone isolated from the heartwood of red lapacho. The compound gives rise to several pharmacologically important isomers upon chemical transformation:

Although lapachol was discarded by the National Cancer Institute, its two other isomers (α- and β-lapachone) emerged as potential bioactive compounds. α-Lapachone demonstrated trypanocidal and antiangiogenic activities.
β-Lapachone is the minority compound of the three isomers, and the extraction yield from plant material is very poor; therefore, β-lapachone is synthesized from lapachol. β-Lapachone has attracted great attention for its anticancer activity and has already been tested in Phase II clinical trials for the treatment of pancreatic cancer.

Broader Phytochemical Context

Originally isolated from species of the Bignoniaceae family, lapachol can also be found in other families such as Verbenaceae, Proteaceae, Leguminosae, Sapotaceae, Scrophulariaceae, and Malvaceae. The bark also contains additional antimicrobially active quinones, including xyloidone, which is a naturally occurring o-naphthoquinone distinct from lapachol. Lapachol has been shown to have both antimicrobial and antiviral activity; beta-lapachone shows diversified antiparasitic activity as well as antiviral action; alpha-lapachone is also active against certain parasites; and xyloidone is active against numerous bacteria and fungi.

4. Mechanisms of Action

Respiratory Chain Inhibition and Oxidative Phosphorylation Uncoupling

Lapachol, like many naphthoquinones, interferes with the electron transport system and inhibits the cell respiratory mechanism. Lapachol has been shown to act as an uncoupler of oxidative phosphorylation. Lapachol prevents the synthesis of adenosine triphosphate by stimulating respiration in the absence of a phosphate acceptor. It is hypothesized that lapachol either inhibits the interaction between the cytochromes b and c or directly inhibits an unknown enzyme between the two cytochromes.

Topoisomerase Inhibition

The mechanisms related to cytotoxic activity are based on inhibitory action of topoisomerases I and II and the induction of oxidative stress by the intracellular formation of reactive oxygen species, damaging cell structures. Activity through the inhibition of topoisomerase I and II, promoting cellular apoptosis, has been observed.

Reactive Oxygen Species (ROS) Generation and Apoptosis

The principal mechanism of action is the ability to increase the generation of ROS, thereby being responsible for causing DNA damage and triggering apoptosis through the intrinsic pathway. Lapachol induces the generation of ROS, which damages DNA and afterward promotes apoptosis. Beta-lapachone is bioactivated by NAD(P)H:quinone oxidoreductase-1 (NQO1), creating a futile oxidoreduction that generates high levels of superoxide. In turn, the highly reactive oxygen species (ROS) interact with DNA, thereby causing single-strand DNA breaks and calcium release.

Enzyme Inhibition

Lapachol inhibits certain enzymes; in particular, it is a competitive inhibitor of glycolase I in erythrocytes. Lapachol also demonstrates noncompetitive inhibition of α-keto-aldehyde dehydrogenase, leading to the accumulation of toxic α-ketoaldehydes. Lapachol demonstrated 64% inhibition of 3-α-hydroxysteroid-mediated transhydrogenase at a concentration of 10^-5M.

Vitamin K Antagonism

Lapachol proved to be a vitamin K-antagonist, thus possibly targeting vitamin K-dependent reactions, besides also being bio-activated by P450 reductase to reactive species which promote DNA scission, through redox cycling with generation of free radicals.

Antifungal Mechanism

The presumed antifungal activity of lapachol is believed to be due to its interaction with the cellular membrane.

Anti-inflammatory Mechanisms (β-Lapachone, a Structural Congener)

β-Lapachone inhibited the expression of iNOS, proinflammatory cytokines, and matrix metalloproteinases (MMP-3, MMP-8, MMP-9) at mRNA and protein levels in LPS-stimulated microglia. On the other hand, β-lapachone upregulated the expressions of anti-inflammatory molecules such as IL-10, heme oxygenase-1 (HO-1), and the tissue inhibitor of metalloproteinase-2 (TIMP-2). Further mechanistic studies revealed that β-lapachone exerts anti-inflammatory effects by inhibiting MAPKs, PI3K/AKT, and NF-κB/AP-1 signaling pathways in LPS-stimulated microglia.

5. Scientific Evidence by Area of Use

5.1 Oncology (Anticancer Activity)

Preclinical (In Vitro and Animal) Evidence

Lapachol showed significant in vivo anti-tumor activity in several early mouse models, since then progressing to clinical trials by the National Cancer Institute (NCI) in the 1970s. Balassiano et al. analyzed the effects of lapachol on a human cancer cell line and evaluated the potential of this substance as an anti-metastatic drug using an in vivo assay. The results indicated that lapachol, in the maximal non-toxic concentration for HeLa cells of 400 µg/ml, induces alterations in the protein profile and inhibits cellular invasiveness, thus representing an important anti-metastatic activity.

β-Lapachone had a high cytotoxic capacity for all cell lines tested: ACP02 (gastric adenocarcinoma cells), MCF7 (breast carcinoma cells), HCT116 (colon cancer cells), and HEPG2 (hepatocellular carcinoma cells). β-Lapachone exhibited the strongest antiproliferative activity against HeLa, MCF-7, and A549 cancer cell lines, with IC50 values ranging from 2.85 to 6.24 µM, approaching the activity of doxorubicin under the same in vitro conditions.

Research shows these compounds may interfere with DNA replication and RNA synthesis, thereby inhibiting the proliferation of cancer cells.

Human/Clinical Evidence

Because of the folklore information surrounding the tumor-reducing qualities of the herb lapacho, it underwent extensive study by the NCI. After the initial positive results, lapachol was judged to be the most active antineoplastic agent. Lapachol entered Phase I clinical trials at the NCI in 1968 on the basis of its activity against Walker 256 tumors (with a confidence rate exceeding 90%).

During these trials, it was difficult to obtain therapeutic blood levels of lapachol without some mild toxic side effects, such as nausea, vomiting, and anti-vitamin K activity. The investigative new drug (IND) status for the drug was closed in 1970 due to these toxicity issues.

In 1974, the National Cancer Institute demonstrated in a Phase I clinical trial that lapachol was not an effective treatment of cancer due to lack of a therapeutic window, and this essentially terminated further clinical research at the time.

Lapachol, a compound present in Pau d'arco, did not show clinical improvement in patients with chronic myelocytic leukemia.

Small studies showed that a lapacho-based preparation may help prevent oral mucositis in patients with head and neck cancer undergoing radiotherapy. These findings are described as preliminary.

Evidence strength: To date, no clinical trial has confirmed the effectiveness of lapacho in treating cancers. The great interest in lapachol decreased after a failure of Phase I clinical trials, where it showed toxicity and no therapeutic response. The anticancer evidence for lapachol itself, in humans, is negative from the only clinical data available. Research interest has shifted toward derivatives, particularly β-lapachone.

5.2 Antimicrobial Activity

Antibacterial

As an antimicrobial, lapachol is an effective inhibitor of the Brucella genus, Bacillus subtilis, Escherichia coli, Pseudomonas aeruginosa, Salmonella typhimurium, Enterococcus faecalis, Candida sp., and Micrococcus pyogenes. It is particularly more effective against Gram-positive bacteria. It was also found that lapachol has activity against H. pylori, Staphylococcus, Streptococcus, Enterococcus, Bacillus, and Clostridium species, with an MIC ranging from 1.56 to 25 mcg/ml.

The thiosemicarbazone and semicarbazone derivatives of lapachol exhibited antimicrobial activity against the bacteria Enterococcus faecalis and Staphylococcus aureus with minimal inhibitory concentrations (MICs) of 0.05 and 0.10 µmol/mL, respectively.

Antifungal

It was reported that lapachol has a significant effect against Candida albicans, Candida tropicalis, and Cryptococcus neoformans, that was similar to Amphotericin B. The thiosemicarbazone and semicarbazone derivatives were also active against the pathogenic yeast Cryptococcus gattii (MICs of 0.10 and 0.20 µmol/mL, respectively). In addition, the lapachol thiosemicarbazone derivative was active against 11 clinical isolates of Paracoccidioides brasiliensis, with MICs ranging from 0.01–0.10 µmol/mL. These specialized metabolites have also shown beneficial antimicrobial effects against Coccidioides posadasii, Cryptococcus neoformans, Staphylococcus hemolyticus, methicillin-resistant Staphylococcus aureus, rifampicin-resistant Mycobacterium tuberculosis, and fluconazole-resistant Candida albicans.

Evidence strength: All antimicrobial data for lapachol are currently limited to in vitro and, to a lesser extent, in vivo (animal) models. Laboratory studies showed that pau d'arco has antibacterial and antifungal activities. It has not been tested in humans in controlled clinical trials for these specific indications. Evidence is therefore considered preliminary and not confirmed in human trials.

5.3 Antimalarial Activity

Lapachol is an abundant prenyl naphthoquinone occurring in Brazilian Bignoniaceae that was clinically used, in former times, as an antimalarial drug, despite its moderate effect. In a study done in the 1940s, it was found that lapachol at a concentration of 100 mg/ml inhibits the uptake of oxygen in Plasmodium Knowles by 74% and the succinate oxidase system by 26%. These findings led to the conclusion that lapachol exhibits antimalarial activity against Plasmodium lapohurae via respiratory inhibition as a likely mechanism. However, the exact mechanism of action remains controversial.

Evidence strength: Antimalarial use preceded modern clinical trial methodology. Modern in vitro data confirm biological activity, with lapachol showing an IC50 of 123.5 μM against chloroquine-resistant Plasmodium falciparum (W2), but this activity is considered moderate. No contemporary human clinical trial has confirmed efficacy for malaria.

5.4 Antiparasitic Activity

Leishmaniasis

Lapachol, an abundant naphthoquinone extracted from American Handroanthus species, demonstrated promising in vitro and in vivo activities against L. infantum and L. amazonensis, which are responsible for visceral and cutaneous leishmaniasis, respectively. Lapachol induced apoptosis-like death in Leishmania promastigotes and in vivo reduced the parasitic load in skin lesions, liver, and spleen.

The lethal dose (LD50) at 24, 48, and 72 hours on promastigote forms using lapachol was 75.60, 72.82, and 58.85 μg/mL, and lapachol significantly inhibited the survival rate of L. amazonensis amastigotes at 83.11%, 57.59%, and 34.95% at concentrations of 82.28, 41.14, and 20.57 µg/mL.

However, lapachol was evaluated in vitro against intracellular amastigotes of Leishmania braziliensis and then tested in an animal model (hamster). In vitro, lapachol exhibited an anti-amastigote effect, whereas in vivo it did not prevent the development of Leishmania-induced lesions. This discrepancy between in vitro and in vivo results highlights the translational challenges in this research area.

Schistosomiasis

Recent results have shown that lapachol, isolapachol, and its acetyl derivative are significantly active against Biomphalaria glabrata, the intermediate host of Schistosoma mansoni. The potassium salts of isolapachol and lapachol showed significant molluscicidal activity against the adult snail (LC90 <7 ppm) and snail egg masses (LC90 <3 ppm). Cercaricidal assays revealed strong activities for both compounds.

Toxocariasis

A study was conducted to evaluate the in vitro activity of lapachol, β-lapachone, and phenazines in relation to the viability of Toxocara canis larvae. A concentration of 2 mg/mL of the compounds was tested using microculture plates containing Toxocara canis larvae in an RPMI-1640 environment, incubated at 37°C in 5% CO2 tension for 48 hours.

Evidence strength for antiparasitic uses: Evidence is predominantly from in vitro studies and animal models. No human clinical trial data are available for lapachol in leishmaniasis, schistosomiasis, or toxocariasis.

5.5 Antiviral Activity

Lapachol has proved to be active against certain viral strains, including herpesvirus hominis types I and II. Lapachol was found to be active against certain viral strains including herpes virus types I and II. Naphthoquinones have been documented to show effectiveness against four strains of the flu, polio, and vesicular stomatitis virus.

Evidence strength: All antiviral data are from laboratory (in vitro) studies. No human clinical trials have evaluated lapachol for antiviral indications.

5.6 Anti-inflammatory Activity

The anti-inflammatory properties of lapachol have been studied in preclinical settings. Oxygen consumption and oxygen metabolite production are inhibited in neutrophils on the administration of lapachol. Lapachol's congener β-lapachone has been shown, in cell studies, to inhibit the expression of iNOS, proinflammatory cytokines, and matrix metalloproteinases, and to attenuate NF-κB signaling, though these findings are specific to β-lapachone rather than lapachol itself.

Evidence strength: Anti-inflammatory evidence for lapachol is limited to in vitro and early animal models. No controlled human trial has confirmed anti-inflammatory efficacy for lapachol specifically.

5.7 Oral Mucositis in Cancer Patients

Preliminary findings suggest benefits of pau d'arco in preventing oral mucositis in patients with head and neck cancer undergoing radiotherapy, based on a small clinical study. These findings remain preliminary and have not been replicated in adequately powered randomized controlled trials.

5.8 Dysmenorrhea

Preliminary findings also suggest a reduction in pain in women with primary dysmenorrhea based on an early open-label study. Evidence here is preliminary, with no phase II or III randomized data available.

6. Body Systems and Health Areas Associated with Lapachol

Oncology: Historically investigated for anticancer potential; Phase I trials conducted by the NCI were ultimately negative for lapachol as a standalone agent; derivative β-lapachone remains under investigation.
Infectious Disease / Microbiology: Antibacterial, antifungal, and antiviral activities demonstrated in laboratory settings; no confirmed human clinical evidence.
Parasitology: Activity against Leishmania, Trypanosoma, Schistosoma, and Toxocara demonstrated in vitro and in some animal models.
Hematology / Coagulation: Lapachol acts as a vitamin K antagonist, affecting coagulation pathways — both a mechanism relevant to its antiparasitic activity and a safety liability.
Gynecology: Preliminary evidence regarding primary dysmenorrhea.
Oncological Supportive Care: Preliminary evidence for reduction of oral mucositis during head and neck cancer radiotherapy.
Immunology / Inflammation: In vitro modulation of inflammatory mediators; no human data for lapachol specifically.

7. Dosage Forms and Dosages Reported in Studies

Traditionally, one-half to one cup of bark and/or heartwood decoction is taken orally 2–4 times daily.

A clinical study indicates that at doses above 1.5 g per day, lapachol significantly increases the risk of bleeding.

Lapachol entered Phase I clinical trials at the NCI in 1968 on the basis of its activity against Walker 256 tumors (with a confidence rate exceeding 90%). The specific human dose used in the NCI Phase I trial was not achievable at a non-toxic level, as it was difficult to obtain therapeutic blood levels of lapachol without some mild toxic side effects, such as nausea, vomiting, and anti-vitamin K activity.

In vitro, lapachol at the maximal non-toxic concentration for HeLa cells of 400 µg/ml (corresponding to 10¹² molecules of the drug/cell) induced alterations in the protein profile and inhibited cellular invasiveness.

Commercial products containing pau d'arco are available in capsule, tablet, extract, powder, and tea forms. No standardized or approved therapeutic dosage has been established for lapachol as an isolated compound, and the NCI Phase I experience demonstrated that an adequate therapeutic window does not exist for the isolated compound in oncological applications.

8. Safety Considerations and Drug Interactions

Toxicity Profile Identified in Clinical and Preclinical Studies

The NCI concluded that the high concentrations required for efficient chemotherapy in human cancer treatment, unfortunately also gave rise to extremely toxic side-effects, thereby justifying its rejection. Reported clinical adverse effects during the NCI trials included nausea, vomiting, and anti-vitamin K activity.

Reported adverse effects include nausea, vomiting, and urine discoloration. Animal studies have reported anemia and reproductive and chromosomal abnormalities.

Anticoagulant / Vitamin K Antagonism

Lapacho could increase the risk of bleeding when combined with anticoagulant or antiplatelet drugs or supplements. In vitro studies show that it reduces platelet aggregation and could interfere with vitamin K, an essential factor in coagulation. These effects are attributed mainly to lapachol, its active compound. A clinical study indicates that at doses above 1.5 g per day, lapachol significantly increases the risk of bleeding.

It has been shown that some of the anthraquinones in lapacho have vitamin K activity; therefore use of the whole herb may compensate for lapachol's effect on vitamin K. This counterbalancing effect of whole-plant preparations versus isolated lapachol is an important pharmacological distinction.

Drug Interactions

Pau d'arco may increase the risk of bleeding when taken with anticoagulants or antiplatelet drugs. Lapacho could also interact with herbs and supplements that have anticoagulant or antiplatelet effects, such as ginkgo biloba, turmeric, or garlic, increasing the risk of bleeding.

Reproductive Toxicity and Teratogenicity

Animal studies show teratogenic and abortifacient effects related to lapachol. This reproductive toxicity signal, consistent with the traditional use of lapacho-derived preparations as an abortifacient in some indigenous traditions, makes the compound contraindicated in pregnancy in its isolated form, based on available preclinical data.

Genotoxicity

A study investigated the genotoxicity of lapachol using the wing spot test of Drosophila melanogaster. This assay detects the loss of heterozygosity of marker genes expressed phenotypically on the fly's wings. Drosophila has extensive genetic homology to mammals, which makes it a suitable model organism for genotoxic investigations. The results showed that lapachol is a promutagen, exhibiting genotoxic activity in larvae from the high-bioactivation cross. An increase in the frequency of spots is exclusive of individuals with a high level of cytochrome P450. The results also indicate that recombinogenicity is the main genotoxic event induced by lapachol. This means that lapachol's genotoxic potential is dependent on metabolic activation by cytochrome P450, and its genotoxic risk may vary by individual metabolizer status.

Narrow Therapeutic Window

Lapachol and beta-lapachone, while biologically powerful, have safety issues that limit their use as standalone drugs. The failure of Phase I trials was specifically due to substantial systemic toxicity and insufficient therapeutic efficacy at tolerable concentration levels. Consequently, the National Cancer Institute discontinued the clinical development of lapachol.

Product Quality and Standardization Concerns

Analyses of commercial products show wide variation in species used, plant parts, and levels of lapachol and related compounds. Some "pau d'arco" capsules contain little or no characteristic naphthoquinones. This makes it difficult to compare studies and to translate research findings into real-world products.

9. Current Research Status and Future Directions

The research landscape around lapachol has shifted considerably since the NCI's mid-20th-century trials. Although lapachol was discarded by the National Cancer Institute, its two isomers (α- and β-lapachone) emerged as potential bioactive compounds. β-Lapachone has already been tested in Phase II clinical trials for the treatment of pancreatic cancer.

Ethnobotanical and experimental (in vitro) evidence supports the use of Tabebuia species for treating infectious diseases. The compounds responsible for their antimicrobial activity have been isolated, and their structures have been elucidated, emphasizing among them naphthoquinones such as lapachol. Natural products isolated from Tabebuia plants may be an alternative for developing new anti-infectious agents.

A series of 1,2,3-triazole derivatives was synthesized by chemical modification of lapachol in an effort to improve antimalarial activity and reduce toxicity, representing a broader trend toward semi-synthetic derivatives of lapachol as potentially safer and more selective pharmacological agents.

References

Condiciones de Salud

Condiciones de salud que Lapachol puede ayudar a apoyar.

Energía (falta de)Científico
Lapachol is a naphthoquinone extracted from pau d'arco (Tabebuia spp.) bark with documented in vitro antifungal activity against Candida albicans and Candida tropicalis, comparable to pharmaceutical antifungals in one 2007 study. It disrupts fungal electron transport and cell membranes. Lapachol is the primary active antifungal constituent of pau d'arco bark.

Sistemas Corporales

Sistemas corporales que Lapachol puede ayudar a apoyar.

No hay sistemas corporales disponibles.